Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Watson Labs Teva

Pharmaceutical intelligence for Watson Labs Teva with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
1
Assets
3

Recent signals(3)

RegulatoryAugust 11, 2026

FDA grants AP status for Simvastatin ANDA076685 by Watson Labs Teva

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA076685) for Simvastatin submitted by Watson Labs Teva.

RegulatoryAugust 7, 2026

FDA Grants AP Status for Minocycline Hydrochloride by Watson Labs Teva

The FDA has granted Abbreviated Approval (AP) status for Minocycline Hydrochloride submitted by Watson Labs Teva.

RegulatoryJune 29, 2026

FDA Acceptance of Supplement for Buprenorphine by Watson Labs Teva

The FDA has accepted a supplemental application for buprenorphine from Watson Labs Teva.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(3)

RegulatoryAugust 11, 2026

FDA grants AP status for Simvastatin ANDA076685 by Watson Labs Teva

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA076685) for Simvastatin submitted by Watson Labs Teva.

RegulatoryAugust 7, 2026

FDA Grants AP Status for Minocycline Hydrochloride by Watson Labs Teva

The FDA has granted Abbreviated Approval (AP) status for Minocycline Hydrochloride submitted by Watson Labs Teva.

RegulatoryJune 29, 2026

FDA Acceptance of Supplement for Buprenorphine by Watson Labs Teva

The FDA has accepted a supplemental application for buprenorphine from Watson Labs Teva.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

buprenorphine →
FDA →
Simvastatin →

Therapeutic areas

Antibiotic →
Cardiovascular →
Cholesterol Management →
Infectious Disease →
Opioid →
Pain Management →
Pain Management · Opioid →

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.